Roche presented new data at ECTRIMS 2025 confirming that OCREVUS provides sustained protection against disability progression and maintains a con ...

In view of persistent fever and cough, and the new onset of an accentuated confluent maculopapular rash, the patient was ...

In June 2024, Nkarta announced the initiation of Ntrust-I, a multi-center clinical trial of NKX019 in lupus nephritis, with ...

Objectives Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterised by multiorgan involvement.

FLORENCE — HopeHealth announced Aug. 29 it is participating in a pivotal phase 3 clinical research study, sponsored by global pharmaceutical company Bristol Myers Squibb, to evaluate an ...

Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today ...

WASHINGTON, Aug. 27, 2025 /PRNewswire/ -- The Lupus Foundation of America is pleased to announce the recipients of the 2025 Gary S. Gilkeson Career Development Award (CDA). The two-year grant supports ...

Early-career and postdoctoral awardees aim to fuel discoveries to improve the lives of people living with lupus NEW YORK, Aug. 5, 2025 /PRNewswire/ -- Today, the Lupus Research Alliance (LRA), the ...

Today, the Lupus Research Alliance (LRA), the world's largest private funder of lupus research, announced the recipients of the 2025 Empowering Lupus Research (ELR) Career Development Award and ...

One of the genes increased with L-sepiapterin is known to be reduced in the kidney in Type 2 diabetes. "This suggests that L-sepiapterin has potential not only in the treatment of lupus nephritis but ...

Victoria P. Werth, MD, professor of dermatology at the University of Pennsylvania Hospital, and chief of dermatology at the Philadelphia VA Hospital, discusses recent developments for the treatment of ...